Antimicrobial peptide-based treatment for endodontic infections - Biotechnological innovation in endodontics

Biotechnology Advances

Volumn 33, Issue 1, 2015, Pages 203-213

  Lima, Stella Maris de Freitas ^a   de Pádua, Gabriela Martins ^a   Sousa, Maurício Gonçalves da Costa ^a   Freire, Mirna de Souza ^a,b   Franco, Octávio Luiz ^a,b,c   Rezende, Taia Maria Berto ^a,d  

^a UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^b Programa de Doutorado da Rede Centro Oeste   (Brazil)

^c UNIVERSIDADE CATÓLICA DOM BOSCO   (Brazil)

^d UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Antimicrobial peptide; Endodontic disinfection; Endodontic microbiology; Intracanal dressing

Indexed keywords

ANTIMICROBIAL AGENTS; BONE; CANALS; HYDRAULIC STRUCTURES; IMMUNE SYSTEM; MICROBIOLOGY; PATENTS AND INVENTIONS; PEPTIDES; POLYPEPTIDES;

ANTI-MICROBIAL ACTIVITY; ANTIMICROBIAL PEPTIDE; ANTIMICROBIAL PERFORMANCE; ENDODONTIC TREATMENT; IMMUNE RESPONSE; IMMUNOMODULATORY; INHIBITORY CONCENTRATION; SYNTHETIC PEPTIDE;

MICROORGANISMS;

ANTIMICROBIAL ACTIVITY; BIOTECHNOLOGY; BONE; DISINFECTION; IMMUNE RESPONSE; INNOVATION; PEPTIDE;

BACTERIA (MICROORGANISMS); BOVINAE;

ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE;

ANIMAL; DRUG EFFECTS; ENDODONTICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MICROFLORA; PERIAPICAL PERIODONTITIS;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIOTA; PERIAPICAL PERIODONTITIS; ROOT CANAL THERAPY;

EID: 84922778233     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2014.10.013     Document Type: Review

References (120)

1. Ando K., Mori K., Corradini N., Redini F., Heymann D. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother 2011, 12:285-292.
2. Athanassiadis B., Abbott P.V., Walsh L.J. The use of calcium hydroxide, antibiotics and biocides as antimicrobial medicaments in endodontics. Aust Dent J 2007, 52:S64-S82.
3. Ballal V., Kundabala M., Acharya S., Ballal M. Antimicrobial action of calcium hydroxide, chlorhexidine and their combination on endodontic pathogens. Aust Dent J 2007, 52:118-121.
4. Banck M.S., Beutler A.S. Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 2014, 30:163-167.
5. Barekatain B., Hasheminia S.M., Shadmehr E., Attary Z. The effect of calcium hydroxide placement on pH and calcium concentration in periapical environment: an in vitro study. Indian J Dent Res 2012, 23:226-229.
6. Bartie K.L., Devine D.A., Wilson M.J., Lewis M.A. In vitro susceptibility of the Streptococcus milleri group to antimicrobial peptides. Int Endod J 2008, 41:586-592.
7. Bas M., Greve J., Hoffmann T.K., Reshef A., Aberer W., Maurer M., et al. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy 2013, 68:1452-1459.
8. Baumgartner J.C., Falkler W.A. Bacteria in the apical 5mm of infected root canals. J Endod 1991, 17:380-383.
9. Beckloff N., Laube D., Castro T., Furgang D., Park S., Perlin D., et al. Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens. Antimicrob Agents Chemother 2007, 51:4125-4132.
10. Bierbaum G., Sahl H.G. Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes. Arch Microbiol 1985, 141:249-254.
11. Brito L.C., Teles F.R., Teles R.P., Totola A.H., Vieira L.Q., Sobrinho A.P. T-lymphocyte and cytokine expression in human inflammatory periapical lesions. J Endod 2012, 38:481-485.
12. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat Rev Microbiol 2005, 3:238-250.
13. Bystrom A., Sundqvist G. The antibacterial action of sodium hypochlorite and EDTA in 60 cases of endodontic therapy. Int Endod J 1985, 18:35-40.
14. Bystrom A., Claesson R., Sundqvist G. The antibacterial effect of camphorated paramonochlorophenol, camphorated phenol and calcium hydroxide in the treatment of infected root canals. Endod Dent Traumatol 1985, 1:170-175.
15. Cafini F., Aguilar L., Gonzalez N., Gimenez M.J., Torrico M., Alou L., et al. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother 2007, 59:1185-1189.
16. Caron P.J., Bevan J.S., Petersenn S., Flanagan D., Tabarin A., Prevost G., et al. Tumor Shrinkage with Lanreotide Autogel 120mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial. J Clin Endocrinol Metab 2014, 99:1282-1290.
17. Chandrudu S., Simerska P., Toth I. Chemical methods for peptide and protein production. Molecules 2013, 18:4373-4388.
18. Cleveland J., Montville T.J., Nes I.F., Chikindas M.L. Bacteriocins: safe, natural antimicrobials for food preservation. Int J Food Microbiol 2001, 71:1-20.
19. Clyne M. Prostate cancer: Tipping the balance in favour of degarelix for ADT. Nat Rev Urol 2014, 11:67.
20. Conrads G., Gharbia S.E., Gulabivala K., Lampert F., Shah H.N. The use of a 16s rDNA directed PCR for the detection of endodontopathogenic bacteria. J Endod 1997, 23:433-438.
21. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 1999, 284:1318-1322.
22. Cross K.J., Huq N.L., Reynolds E.C. Casein phosphopeptides in oral health-chemistry and clinical applications. Curr Pharm Des 2007, 13:793-800.
23. Dale B.A., Tao R., Kimball J.R., Jurevic R.J. Oral antimicrobial peptides and biological control of caries. BMC Oral Health 2006, 6(Suppl. 1):S13.
24. Devine D.A., Marsh P.D., Percival R.S., Rangarajan M., Curtis M.A. Modulation of antibacterial peptide activity by products of Porphyromonas gingivalis and Prevotella spp. Microbiology 1999, 145:965-971.
25. Eberhard J., Pietschmann R., Falk W., Jepsen S., Dommisch H. The immune response of oral epithelial cells induced by single-species and complex naturally formed biofilms. Oral Microbiol Immunol 2009, 24:325-330.
26. Eckert R. Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development. Future Microbiol 2011, 6:635-651.
27. Farber P.A., Seltzer S. Endodontic microbiology. I. Etiology. J Endod 1988, 14:363-371.
28. Figdor D. Microbial aetiology of endodontic treatment failure and pathogenic properties of selected species. Aust Endod J 2004, 30:11-14.
29. Figdor D., Davies J.K., Sundqvist G. Starvation survival, growth and recovery of Enterococcus faecalis in human serum. Oral Microbiol Immunol 2003, 18:234-239.
30. Foschi F., Izard J., Sasaki H., Sambri V., Prati C., Muller R., et al. Treponema denticola in disseminating endodontic infections. J Dent Res. 2006, 85:761-765.
31. Fouad A.F., Barry J., Caimano M., Clawson M., Zhu Q., Carver R., et al. PCR-based identification of bacteria associated with endodontic infections. J Clin Microbiol 2002, 40:3223-3231.
32. Fukada S.Y., Silva T.A., Garlet G.P., Rosa A.L., da Silva J.S., Cunha F.Q. Factors involved in the T helper type 1 and type 2 cell commitment and osteoclast regulation in inflammatory apical diseases. Oral Microbiol Immunol 2009, 24:25-31.
33. Gajan E.B., Aghazadeh M., Abashov R., Milani A.L., Moosavi Z. Microbial flora of root canals of pulpally-infected teeth: Enterococcus faecalis a prevalent species. J Dent Res Dent Clin Dent Prospect 2009, 3:24-27.
34. Giles F.J., Redman R., Yazji S., Bellm L. Iseganan HCl: a novel antimicrobial agent. Expert Opin Investig Drugs 2002, 11:1161-1170.
35. Giuliani A., Pirri G., Nicoletto S.F. Antimicrobial peptides: an overview of a promising class of therapeutics. Cent Eur J Biol 2007, 2:1-33.
36. Gomes B.P., Lilley J.D., Drucker D.B. Associations of endodontic symptoms and signs with particular combinations of specific bacteria. Int Endod J 1996, 29:69-75.
37. Gomes B.P., Pinheiro E.T., Gade-Neto C.R., Sousa E.L., Ferraz C.C., Zaia A.A., et al. Microbiological examination of infected dental root canals. Oral Microbiol Immunol 2004, 19:71-76.
38. Gorni F.G., Gagliani M.M. The outcome of endodontic retreatment: a 2-yr follow-up. J Endod 2004, 30:1-4.
39. Gorr S.U., Abdolhosseini M. Antimicrobial peptides and periodontal disease. J Clin Periodontol 2011, 38(Suppl. 11):126-141.
40. Guo H.J., Wang J.D. Bacterial biofilm on the apical external root surfaces of human teeth associated with chronic periradicular lesions. Beijing Da Xue Xue Bao 2009, 41:571-574.
41. Gurkan A., Emingil G., Nizam N., Doganavsargil B., Sezak M., Kutukculer N., et al. Therapeutic efficacy of vasoactive intestinal peptide in Escherichia coli lipopolysaccharide-induced experimental periodontitis in rats. J Periodontol 2009, 80:1655-1664.
42. Gursoy U.K., Kononen E., Luukkonen N., Uitto V.J. Human neutrophil defensins and their effect on epithelial cells. J Periodontol 2013, 84:126-133.
43. Haapasalo M. Bacteroides spp. in dental root canal infections. Endod Dent Traumatol 1989, 5:1-10.
44. Hancock R.E., Falla T., Brown M. Cationic bactericidal peptides. Adv Microb Physiol 1995, 37:135-175.
45. Henriques L.C., de Brito L.C., Tavares W.L., Vieira L.Q., Ribeiro Sobrinho A.P. Cytokine analysis in lesions refractory to endodontic treatment. J Endod 2011, 37:1659-1662.
46. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010, 5:109-117.
47. Hong S.Y., Park T.G., Lee K.H. The effect of charge increase on the specificity and activity of a short antimicrobial peptide. Peptides 2001, 22:1669-1674.
48. Hong R.W., Shchepetov M., Weiser J.N., Axelsen P.H. Transcriptional profile of the Escherichia coli response to the antimicrobial insect peptide cecropin A. Antimicrob Agents Chemother 2003, 47:1-6.
49. Hosokawa I., Hosokawa Y., Ozaki K., Nakae H., Matsuo T. Adrenomedullin suppresses tumour necrosis factor alpha-induced CXC chemokine ligand 10 production by human gingival fibroblasts. Clin Exp Immunol 2008, 152:568-575.
50. Jancso N., Jancso-Gabor A., Szolcsanyi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother 1967, 31:138-151.
51. Ji S., Hyun J., Park E., Lee B.L., Kim K.K., Choi Y. Susceptibility of various oral bacteria to antimicrobial peptides and to phagocytosis by neutrophils. J Periodontal Res 2007, 42:410-419.
52. Kawakami J., Morales A. Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists. Can Urol Assoc J 2013, 7:E226-E230.
53. Kluver E., Schulz-Maronde S., Scheid S., Meyer B., Forssmann W.G., Adermann K. Structure-activity relation of human beta-defensin 3: influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry (Mosc) 2005, 44:9804-9816.
54. Kragol G., Lovas S., Varadi G., Condie B.A., Hoffmann R., Otvos L. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry (Mosc) 2001, 40:3016-3026.
55. Laverty G., Gilmore B. Cationic antimicrobial peptide cytotoxicity. SOJ Microbiol Infect Dis 2014, 2:1-8.
56. Lee S.H., Baek D.H. Antibacterial and neutralizing effect of human beta-defensins on Enterococcus faecalis and Enterococcus faecalis lipoteichoic acid. J Endod 2012, 38:351-356.
57. Lee J.K., Chang S.W., Perinpanayagam H., Lim S.M., Park Y.J., Han S.H., et al. Antibacterial efficacy of a human beta-defensin-3 peptide on multispecies biofilms. J Endod 2013, 39:1625-1629.
58. Lee J.K., Park Y.J., Kum K.Y., Han S.H., Chang S.W., Kaufman B., et al. Antimicrobial efficacy of a human beta-defensin-3 peptide using an Enterococcus faecalis dentine infection model. Int Endod J 2013, 46:406-412.
59. Lucchese A., Guida A., Petruzzi M., Capone G., Laino L., Serpico R. Peptides in oral diseases. Curr Pharm Des 2012, 18:782-788.
60. Lyu T., Zhao Y., Zhang T., Zhou W., Yang F., Ge H., et al. Natriuretic peptides as an adjunctive treatment for acute myocardial infarction. Int Heart J 2014, 55:8-16.
61. Mason J.M. Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention. Future Med Chem 2010, 2:1813-1822.
62. Montville T.J., Chen Y. Mechanistic action of pediocin and nisin: recent progress and unresolved questions. Appl Microbiol Biotechnol 1998, 50:511-519.
63. Oguntebi B., Slee A.M., Tanzer J.M., Langeland K. Predominant microflora associated with human dental periapical abscesses. J Clin Microbiol 1982, 15:964-966.
64. Padilla C., Lobos O., Brevis P., Abaca P., Hubert E. In vitro antibacterial activity of the peptide PsVP-10 against antimicrobial-resistant Enterococcus faecalis isolated from clinical samples. J Antimicrob Chemother 2004, 53:390-392.
65. Peters L.B., Wesselink P.R., van Winkelhoff A.J. Combinations of bacterial species in endodontic infections. Int Endod J 2002, 35:698-702.
66. Ribeiro A.C., Matarazzo F., Faveri M., Zezell D.M., Mayer M.P. Exploring bacterial diversity of endodontic microbiota by cloning and sequencing 16S rRNA. J Endod 2011, 37:922-926.
67. Ricucci D., Siqueira J.F. Fate of the tissue in lateral canals and apical ramifications in response to pathologic conditions and treatment procedures. J Endod 2010, 36:1-15.
68. Rocas I.N., Siqueira J.F., Santos K.R. Association of Enterococcus faecalis with different forms of periradicular diseases. J Endod 2004, 30:315-320.
69. Rocas I.N., Baumgartner J.C., Xia T., Siqueira J.F. Prevalence of selected bacterial named species and uncultivated phylotypes in endodontic abscesses from two geographic locations. J Endod 2006, 32:1135-1138.
70. Rocas I.N., Alves F.R., Santos A.L., Rosado A.S., Siqueira J.F. Apical root canal microbiota as determined by reverse-capture checkerboard analysis of cryogenically ground root samples from teeth with apical periodontitis. J Endod 2010, 36:1617-1621.
71. Rosen G., Sela M.N., Bachrach G. The antibacterial activity of LL-37 against Treponema denticola is dentilisin protease independent and facilitated by the major outer sheath protein virulence factor. Infect Immun 2012, 80:1107-1114.
72. Sassone L., Fidel R., Figueiredo L., Fidel S., Faveri M., Feres M. Evaluation of the microbiota of primary endodontic infections using checkerboard DNA-DNA hybridization. Oral Microbiol Immunol 2007, 22:390-397.
73. Sassone L.M., Fidel R.A., Faveri M., Guerra R., Figueiredo L., Fidel S.R., et al. A microbiological profile of symptomatic teeth with primary endodontic infections. J Endod 2008, 34:541-545.
74. Seidel M.G., Urban C., Sipurzynski J., Beham-Schmid C., Lackner H., Benesch M. High response rate but short-term effect of romiplostim in paediatric refractory chronic immune thrombocytopenia. Br J Haematol 2014, 165:419-421.
75. Shimokawa K., Takakuwa R., Taya K., Wada Y., Yamazaki N., Murata M., et al. Adsorption of various antimicrobial agents to endotoxin removal polymyxin-B immobilized fiber (Toraymyxin(R)). Colloids Surf B Biointerfaces 2012, 90:58-61.
76. Silva O.N., Mulder K.C., Barbosa A.E., Otero-Gonzalez A.J., Lopez-Abarrategui C., Rezende T.M., et al. Exploring the pharmacological potential of promiscuous host-defense peptides: from natural screenings to biotechnological applications. Front Microbiol 2011, 2:232.
77. Silva B.R., Freitas V.A., Nascimento-Neto L.G., Carneiro V.A., Arruda F.V., Aguiar A.S., et al. Antimicrobial peptide control of pathogenic microorganisms of the oral cavity: a review of the literature. Peptides 2012, 36:315-321.
78. Silva M.J., Kajiya M., AlShwaimi E., Sasaki H., Hong J., Ok P., et al. Bacteria-reactive immune response may induce RANKL-expressing T cells in the mouse periapical bone loss lesion. J Endod 2012, 38:346-350.
79. Siqueira J.F. Endodontic infections: concepts, paradigms, and perspectives. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002, 94:281-293.
80. Siqueira J.F., Rocas I.N. Clinical implications and microbiology of bacterial persistence after treatment procedures. J Endod 2008, 34:1291-1301.
81. Siqueira J.F., Lopes H.P. Mechanisms of antimicrobial activity of calcium hydroxide: a critical review. Int Endod J 1999, 32:361-369.
82. Siqueira J.F., Rocas I.N. Polymerase chain reaction-based analysis of microorganisms associated with failed endodontic treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004, 97:85-94.
83. Siqueira J.F., Rocas I.N. Diversity of endodontic microbiota revisited. J Dent Res 2009, 88:969-981.
84. Siqueira J.F., Jung I.Y., Rocas I.N., Lee C.Y. Differences in prevalence of selected bacterial species in primary endodontic infections from two distinct geographic locations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005, 99:641-647.
85. Siqueira J.F., Rocas I.N., Lopes H.P. Patterns of microbial colonization in primary root canal infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002, 93:174-178.
86. Siqueira J.F., Rocas I.N., Magalhaes F.A., de Uzeda M. Antifungal effects of endodontic medicaments. Aust Endod J 2001, 27:112-114.
87. Siqueira J.F., Rocas I.N., Souto R., de Uzeda M., Colombo A.P. Checkerboard DNA-DNA hybridization analysis of endodontic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000, 89:744-748.
88. Sjogren U., Hagglund B., Sundqvist G., Wing K. Factors affecting the long-term results of endodontic treatment. J Endod 1990, 16:498-504.
89. Song W., Shi Y., Xiao M., Lu H., Qu T., Li P., et al. In vitro bactericidal activity of recombinant human beta-defensin-3 against pathogenic bacterial strains in human tooth root canal. Int J Antimicrob Agents 2009, 33:237-243.
90. Stashenko P., Teles R., D'Souza R. Periapical inflammatory responses and their modulation. Crit Rev Oral Biol Med 1998, 9:498-521.
91. Strigenz T. Ziconotide. J Pain Palliat Care Pharmacother 2014, 28:73-74.
92. Subramanian K., Mickel A.K. Molecular analysis of persistent periradicular lesions and root ends reveals a diverse microbial profile. J Endod 2009, 35:950-957.
93. Sunde P.T., Tronstad L., Eribe E.R., Lind P.O., Olsen I. Assessment of periradicular microbiota by DNA-DNA hybridization. Endod Dent Traumatol 2000, 16:191-196.
94. Sundqvist G. Associations between microbial species in dental root canal infections. Oral Microbiol Immunol 1992, 7:257-262.
95. Sundqvist G. Ecology of the root canal flora. J Endod 1992, 18:427-430.
96. Taubman M.A., Kawai T. Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. Crit Rev Oral Biol Med 2001, 12:125-135.
97. Teixeira-Salum T.B., Rodrigues D.B., Gervasio A.M., Souza C.J., Rodrigues V., Loyola A.M. Distinct Th1, Th2 and Treg cytokines balance in chronic periapical granulomas and radicular cysts. J Oral Pathol Med 2010, 39:250-256.
98. Teixeira-Salum T.B., Rodrigues D.B., Gervasio A.M., Souza C.J., Rodrigues V., Loyola A.M. Distinct Th1, Th2 and Treg cytokines balance in chronic periapical granulomas and radicular cysts. J Oral Pathol Med 2010, 39:250-256.
99. Thennarasu S., Tan A., Penumatchu R., Shelburne C.E., Heyl D.L., Ramamoorthy A. Antimicrobial and membrane disrupting activities of a peptide derived from the human cathelicidin antimicrobial peptide LL37. Biophys J 2010, 98:248-257.
100. Tomabechi Y., Krippner G., Rendle P.M., Squire M.A., Fairbanks A.J. Glycosylation of pramlintide: synthetic glycopeptides that display in vitro and in vivo activities as amylin receptor agonists. Chemistry 2013, 19:15084-15088.
101. Torabinejad M., Eby W.C., Naidorf I.J. Inflammatory and immunological aspects of the pathogenesis of human periapical lesions. J Endod 1985, 11:479-488.
102. Tossi A., Sandri L., Giangaspero A. Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 2000, 55:4-30.
103. Towfic F., Funt J.M., Fowler K.D., Bakshi S., Blaugrund E., Artyomov M.N., et al. Comparing the biological impact of glatiramer acetate with the biological impact of a generic. PLoS One 2014, 9:e83757.
104. Turner S.R., Love R.M., Lyons K.M. An in-vitro investigation of the antibacterial effect of nisin in root canals and canal wall radicular dentine. Int Endod J 2004, 37:664-671.
105. Urban E., Nagy E., Pal T., Sonnevend A., Conlon J.M. Activities of four frog skin-derived antimicrobial peptides (temporin-1DRa, temporin-1Va and the melittin-related peptides AR-23 and RV-23) against anaerobic bacteria. Int J Antimicrob Agents 2007, 29:317-321.
106. Wang W., Tao R., Tong Z., Ding Y., Kuang R., Zhai S., et al. Effect of a novel antimicrobial peptide chrysophsin-1 on oral pathogens and Streptococcus mutans biofilms. Peptides 2012, 33:212-219.
107. Weistroffer P.L., Joly S., Srikantha R., Tack B.F., Brogden K.A., Guthmiller J.M. SMAP29 congeners demonstrate activity against oral bacteria and reduced toxicity against oral keratinocytes. Oral Microbiol Immunol 2008, 23:89-95.
108. Westerhoff H.V., Juretic D., Hendler R.W., Zasloff M. Magainins and the disruption of membrane-linked free-energy transduction. Proc Natl Acad Sci U S A 1989, 86:6597-6601.
109. Wimley W.C. Describing the mechanism of antimicrobial peptide action with the interfacial activity model. ACS Chem Biol 2010, 5:905-917.
110. Wittrant Y., Gorin Y., Woodruff K., Horn D., Abboud H.E., Mohan S., et al. High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone 2008, 42:1122-1130.
111. Xia T., Baumgartner J.C., David L.L. Isolation and identification of Prevotella tannerae from endodontic infections. Oral Microbiol Immunol. 2000, 15:273-275.
112. Yamaguchi T., Sugimoto T. New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?. Clin Calcium 2009, 19:38-43.
113. Yang L., Weiss T.M., Lehrer R.I., Huang H.W. Crystallization of antimicrobial pores in membranes: magainin and protegrin. Biophys J 2000, 79:2002-2009.
114. Yu F., Lu L., Du L., Zhu X., Debnath A.K., Jiang S. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket. Viruses 2013, 5:127-149.
115. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415:389-395.
116. Zero D.T., Zandona A.F., Vail M.M., Spolnik K.J. Dental caries and pulpal disease. Dent Clin North Am 2011, 55:29-46.
117. Zero D.T., Zandona A.F., Vail M.M., Spolnik K.J. Dental caries and pulpal disease. Dent Clin North Am 2011, 55:29-46.
118. Zhang S., Wang Q.Q., Zhang C.F., Soo I. Identification of dominant pathogens in periapical lesions associated with persistent apical periodontitis. Chin J Dent Res 2010, 13:115-121.
119. Zhou C., Zhang D., Bai Y., Li S. Casein phosphopeptide-amorphous calcium phosphate remineralization of primary teeth early enamel lesions. J Dent 2014, 42:21-29.
120. Zuolo M.L., Ferreira M.O., Gutmann J.L. Prognosis in periradicular surgery: a clinical prospective study. Int Endod J 2000, 33:91-98.